RIO DE JANEIRO, BRAZIL - Gilead Sciences Inc. said an analysis showed its antiviral Remdesivir reduced mortality in patients hospitalized with Covid-19 and increased the likelihood of discharge on day 28 after a five-day course of treatment.
The drugmaker said Monday that it analyzed data on 98,654 patients from three retrospective studies of actual treatment in patients hospitalized with Covid-19.
Remdesivir achieved statistically significant reductions in the risk of death of 54% and 23%, respectively, among patients analyzed in two of the studies, the company said. The data were presented this week at the World Microbe Forum . . .
To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed? Login Here